Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Foxborough, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Evelo Biosciences Inc?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Evelo Biosciences Inc market cap is $1,898.00.
What is the 52-week high for Evelo Biosciences Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Evelo Biosciences Inc 52 week high is $0.0005 as of August 31, 2026.
What is Evelo Biosciences Inc stock price today?
Evelo Biosciences Inc stock price today is $0.0001.